Aravive
study safety profile consistent with the established safety profile for | Aravive
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
23 of 39
Related slides by other companies
ATAI
Investor Presentation
October 2023
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
Nuvalent
Investor Presentation
May 2023
preliminary safety profile favorable and consistent with the highly selective sparing design of | Nuvalent
Nuvalent
Investor Presentation
August 2023
preliminary safety profile favorable and consistent with the highly selective sparing design of | Nuvalent
BenevolentAI
Investor Presentation
October 2022
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights